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Altered networks of gene regulation underlie many pathologies, including cancer. There
are several proteins in cancer cells that are turned either on or off, which dramatically
alters the metabolism and the overall activity of the cell, with the complex machinery of
enzymes involved in the metabolism of glycolipids not being an exception. The aberrant
glycosylation of glycolipids on the surface of the majority of cancer cells, associated with
increasing evidence about the functional role of these molecules in a number of cellular
physiological pathways, has received considerable attention as a convenient immunother-
apeutic target for cancer treatment. This has resulted in the development of a substantial
number of passive and active immunotherapies, which have shown promising results in
clinical trials. More recently, antibodies to glycolipids have also emerged as an attractive
tool for the targeted delivery of cytotoxic agents, thereby providing a rationale for future
therapeutic interventions in cancer. This review first summarizes the cellular and molecu-
lar bases involved in the metabolic pathway and expression of glycolipids, both in normal
and tumor cells, paying particular attention to sialosylated glycolipids (gangliosides). The
current strategies in the battle against cancer in which glycolipids are key players are then
described.
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INTRODUCTION
The aberrant and elevated expression of glycolipids has been
demonstrated on the cell surface of different types of can-
cer cells, with these observations having opened the gate to
the development of traditional immune-based treatment strate-
gies in the battle against cancer. In general, glycolipid vac-
cines have failed to have a significant effect on tumor devel-
opment. More recently, associated with a better comprehen-
sion about the expression, function, and membrane organization
of glycolipids as well as the use of modern technologies, new
immunotherapies have been developed. These therapies involve,
for instance, arming monoclonal antibodies against tumor gly-
colipids with toxins or cytotoxic drugs; the generation of new
glycolipid-specific chimeric antigen receptors in human pri-
mary T-lymphocytes; novel therapies using anti-idiotype mono-
clonal antibodies to sialosylated glycolipids (gangliosides); genet-
ically engineered monoclonal antibodies to gangliosides with
improved efficacy to induce antibody-mediated cellular cytotox-
icity (ADCC); and complement-dependent cytotoxicity (CDC),
among other original and promising immunotherapies.
Multi-institutional consortiums have been recently created
to identify and quantitate all major and many minor lipids
(lipidomic)1 and glycans (glycomic)2 species present mainly in
1http://www.lipidmaps.org
2http://www.functionalglycomics.org
mammalian cells, as well as to quantitate the changes in these
species in response to perturbation. These initiatives are provid-
ing an enormous amount of information, which will certainly be
of great help in the search for new targets in the treatment of
cancer.
GLYCOLIPID STRUCTURE AND SYNTHESIS
Glycolipids are lipids that have a covalently attached carbohy-
drate. Based on the type of lipid, they can be categorized into
three main groups: glycoglycerolipids, glycosylphosphatidylinos-
itols, and glycosphingolipids (GSLs). Mammalian GSLs begin
with either glucose (GlcCer) or galactose (GalCer) attached in
β-linkage to the 1-hydroxyl of ceramide (Cer) or sphingoid. Gal-
Cer can eventually be sulfated to produce acidic GSLs, referred to
as sulfatides. When GlcCer is followed by addition of galactose,
lactosylceramide (LacCer) is produced, which is at a branch point
for formation of the root structure series (globo-, isoglobo-, lacto-,
neolacto-, and ganglio-) (1). In particular, LacCer can be converted
to both the neutral and acidic members of the ganglio-series by
the sequential addition of different monosaccharide units, through
catalytic processes mediated by type II integral membrane glyco-
syltransferases. Among the acidic members of the ganglio-series
are found the gangliosides (Figures 1A,B), which are mono- or
multi-sialosylated GSLs mainly located in the outer layer of the
plasma membrane (PM) of vertebrate cells. In addition, they have
been shown to be present on nuclear membranes, modulating the
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FIGURE 1 | Structure and representative reactions of ganglioside biosynthesis. (A) Chemical structure of the main gangliosides mentioned in this work.
(B) Schematic representation of the main pathway of ganglioside biosynthesis. The full names of the abbreviations are indicated in the text.
intranuclear calcium homeostasis (2). Gangliosides are expressed
in cell-type and developmental-specific patterns, and are major
components of nerve cells, where they may represent more than
10% of the total lipid content. Moreover, on the neuronal surface,
they contribute more than 30% of the N -acetylneuraminic acid
(Neu5Ac or sialic acid) (3–5).
After synthesis of the lipophilic ceramide tail in the endoplas-
mic reticulum (ER), it is then transported to the Golgi complex,
where it is first catalytically converted to GlcCer through UDP-
Glc:ceramide glucosyltransferase (Glc-T) (Figure 2A). Then, most
GlcCer can be transported back to the ER via a four-phosphate
adaptor protein (FAPP2; a glycolipid-transport protein carrying
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FIGURE 2 | Simplified scheme of metabolic pathways of plasma
membrane-associated gangliosides: molecular targets for
immunotherapies in cancer cells. (A) Simplified scheme of metabolic
pathways and intracellular trafficking of gangliosides. Black arrows indicate
the exocytic/biosynthetic pathway. Red arrows indicate the endocytic,
recycling, and catabolic pathway. Dotted arrow indicates the vesicular or
protein mediated transport of ceramide between endoplasmic reticulum (ER)
and the Golgi complex. Green arrows indicate remodeling of
glycosphingolipids by plasma membrane (PM)-associated glycohydrolases
and glycosyltransferases. The hypothetical neobiosynthesis of GM3 at the
Golgi complex and later transport to PM is indicated. De novo synthesized
gangliosides or synthesized at the PM can undergo endocytosis through
clathrin-independent vesicles (caveolae), and once internalized, they can be
recycled back to the PM directly from recycling endosomes (REs) or sorted
from early endosomes (EEs) to the Golgi complex, where they may then be
reglycosylated, or transported to the lysosomes for total or partial
degradation. The representation and colors of ganglioside structures are the
same as in Figure 1. (B) Potential cancer immunotherapies using
gangliosides as molecular targets. Schematic representation depicting the
main cancer immunotherapies involving gangliosides: (1) vaccination with
natural gangliosides or anti-idiotype monoclonal antibodies; (2) humanized
anti-ganglioside antibodies; (3) chimeric T-cell receptors; (4) cancer cell
glycoengineering and monoclonal antibody-mediated selective killing of cells;
(5) targeted delivery of cytotoxic agents using specific antibodies to
gangliosides. See text for more details. The schematic representation and
colors of gangliosides structures are the same as those indicated in Figure 1.
a PI4P binding domain), thereby entering the secretory path-
way for further conversion to LacCer in the luminal face of the
trans Golgi and TGN (6). Other evidence indicates that ceramide
can be glycosylated to GlcCer on the cytosolic leaflet of the
cis Golgi membranes by Glc-T, and also that FAPP2 is then
required for the non-vesicular transport of GlcCer to distal Golgi
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compartments where it then translocates for further glycosylation
steps leading to more complex GSLs synthesis, which eventually
includes gangliosides (7). The synthesis of LacCer occurs by the
action of UDP-Gal:glucosylceramide β-1,4-galactosyltransferase
(Gal-T1), which transfers a galactose residue from UDP-Gal to
GlcCer (Figure 1B). Then, monosaccharide units, including sialic
acid, are transferred from the cognate sugar nucleotide donor
to the glycolipid acceptors produced by the transferases acting
in the preceding steps in the pathway of synthesis. Sialylated
derivatives from LacCer are produced by the action of cytidine
monophosphate (CMP)-NeuAc:LacCer α-2,3-sialyltransferase
(Sial-T1), CMP-NeuAc:GM3 α-2,8-sialyltransferase (Sial-T2),
and CMP-NeuAc:GD3 α-2,8-sialyltransferase (Sial-T3), which
specifically catalyze the formation of the gangliosides GM3,
GD3, and GT3, respectively [ganglioside named according
to Svennerholm (8)] (Figure 1B). LacCer, GM3, GD3, and
GT3 are potentially converted to more complex gangliosides
of the 0-, a-, b-, or c-series by sequential glycosylations
catalyzed by UDP-GalNAc:LacCer/GM3/GD3/GT3 β-1,4-N -
acetylgalactosaminyltransferase (GalNAc-T),UDP-Gal:GA2/GM2
/GD2/GT2 β-1,3-galactosyltransferase (Gal-T2), CMP-NeuAc:
GA1/GM1/GD1b/GT1c α-2,3-sialyltransferase (Sial-T4), and
CMP-NeuAc:GM1b/GD1a/GT1b/GQ1c α-2,8-sialyltransferase
(Sial-T5). These transferases are non-redundant and specific, and
catalyze a sugar transfer to a glycosyl acceptor that differs only
in the number of sialic acids bound to the inner galactose [none
(0-series), one (a-series), two (b-series), or three (c-series)]. Excep-
tionally, the ganglioside GM4 (NeuAcα2,3Gal-Ceramide), a major
component of the myelin, does not derive from LacCer. By the
year 2004, 188 gangliosides with different carbohydrate structures
had been identified in vertebrates (9).
After synthesis, gangliosides leave the Golgi complex via the
lumenal surface of the transport vesicles (10). At the PM, the gan-
gliosides can undergo endocytosis, be recycled back to the PM
directly from early or recycling endosomes (REs), or sorted from
endosomes at the Golgi complex, where they can then be reglyco-
sylated or degraded at the lysosomal level (Figure 2A) (5, 11, 12).
The level of expression and diversity of GSLs, including the
gangliosides, can be controlled by regulating the sugar nucleotide
and acceptor availability and by enzymatic degradation, as well
as through the presence and activity of the glycosyltransferases
that participate in their biosynthesis. Related to this, different
types of regulation of glycosyltransferases have been reported,
i.e., transcriptional, translational, or post-translational (4, 13, 14).
However, an additional type of regulation of GSL expression has
been shown to occur at the PM level, due to PM-associated ecto-
glycohydrolases and glycosyltransferases (3, 15). In particular, an
ectosialyltransferase (ecto-Sial-T2) recently described, it was able
to sialylate GM3 exposed on its own cell or on the membrane of
neighboring cells (16, 17).
GANGLIOSIDE FUNCTION
The development of genetically engineered mice with defects in
distinct biosynthetic steps of ganglioside biosynthesis has revealed
the critical role played by gangliosides in a number of impor-
tant biological processes, especially in the nervous system (18,
19). Gangliosides have been implicated in many physiological
processes, including growth, differentiation, migration, and apop-
tosis through modulating both cell signaling processes and cell-
to-cell and cell-to-matrix interactions (19–25). Moreover, gan-
gliosides have been associated with a wide range of pathological
processes, being receptors for viruses (i.e., simian virus 40), tox-
ins (i.e., cholera; tetanus; and botulinum toxins), lectins, and
antibodies (11, 26, 27). Some antibodies to gangliosides, in par-
ticular to GM1, GD1a, and GQ1b, have been associated with a
wide range of clinically identifiable acute and chronic neuropa-
thy syndromes, including the Guillain–Barré and Miller–Fisher
syndromes (28–31), with antibodies to tumor-associated ganglio-
sides being considered to be potential therapeutic agents, which
are described below in detail (32–34).
GANGLIOSIDE EXPRESSION IN CANCER
Sialic acid-containing GSLs, gangliosides, are present in normal
tissues, but they are highly expressed in many human cancer cells
(Table 1). This is associated with notorious changes in the reper-
tory of expressed species, mainly by altered glycosyltransferase and
glycohydrolase activities. GD2 is a disialoganglioside involved in
cell growth and differentiation, which is highly expressed on neu-
roblastoma, melanoma, glioma, and small-cell lung cancer (SCLC)
cells (35). On the other hand, the expression level of another
disialoganglioside, GD3, is very low and restricted in adult extra
neural tissues. Nevertheless,GD3 is highly expressed in tumor cells,
accounting for more than 80% of melanomas. It is also overex-
pressed in neuroectodermal tumors (neuroblastoma and glioma)
and carcinomas, including lung, breast, colon, prostate, and ovary
cancers (36). In addition, GD3 expression was observed in T-cell
acute lymphoblastic leukemia while being absent in non-T-cell
malignancies (37). For these reasons, ganglioside GD3 has received
considerable attention as being a promising immunotherapeutic
target for cancer therapy. In addition, GM2 is another ganglio-
side overexpressed in a range of cancers, including melanoma and
neuroblastoma (38).
Aberrant sialylation, both in glycoproteins and gangliosides, is
closely associated with the malignant phenotypes of cancer cells,
including metastatic potential and invasiveness. It was also estab-
lished that the expression levels of specific neuraminidases, such as
Neu1 and Neu3, are critical factors in the metastasis and survival
of cancer cells, and that alteration in sialidase expression may be
a defining factor for cancer progression, irrespective of the sialic
acid content (53, 54).
The most common sialic acids in mammals are Neu5Ac and
N -glycolylneuraminic acid (Neu5Gc), which are usually found
as terminal constituents of different membrane glycoconjugates
such as the GM3 ganglioside. Although N -glycolyl gangliosides
are practically undetectable in normal human tissues as a result of
an Alu-mediated inactivation of the gene coding for the enzyme
CMP-NeuAc hydroxylase, these gangliosides are highly expressed
in several human cancer cells (i.e., non-SCLC; Table 1) pre-
sumably due to incorporation of dietary Neu5Gc (55, 56). Fur-
thermore, it has been proposed that the preferential expression
of Neu5Gc in cancers is closely associated with tumor hypoxia,
which induces expression of a sialic acid transporter and enhances
the incorporation of non-human sialic acid from the external
milieu (57).
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Table 1 | Gangliosides expressed in several types of human cancer cells.
Type of tumor GM3 GM2 GM1 GD3 GD2 9-O-
Ac-GD3
9-O-
Ac-GD2
5-N-
de-GM3
Neu5Gc-
GM3
Fucosyl-
GM1
Reference
Melanoma ++ + ++++ +++ + + ++d ++ Morton and Barth (39),
Pukel et al. (40),
Ravindranath et al. (41)
Neuroblastoma ++ + ++++ + Cheung et al. (42),
Hettmer et al. (43),
Kohla et al. (44)
Glioma ++ ++++ Mujoo et al. (35)
SCLCa ++ ++ ++ +++ +++ Brezicka et al. (45),
Yoshida et al. (46, 47)
Non-SCLC +++ +++ van Cruijsen et al. (48)
T-ALLb +++ ++ + Okada et al. (49),
Yamashiro et al. (50)
ATLc ++ ++ Okada et al. (49),
Yamashiro et al. (50)
Breast carcinoma ++ ++ ++ ++ ++ Marquina et al. (51)
Renal carcinoma + ++ + Kudo et al. (52)
Plus signs represent ganglioside expression levels from weak (+) to strong (++++) expression.
aSmall cell lung cancer.
bT-cell acute lymphocytic leukemia.
cAdult T-cell leukemia.
d5-N-deacetylation of GM3 occurred in metastatic melanomas.
GD3 ganglioside can undergo 9-O-acetylation at C9 of the
outer sialic acid (9-O-Ac-GD3) with enhanced expression of the 9-
O-acetylated form of GD3 ganglioside having been demonstrated
in malignant melanomas and in basal cell carcinomas (58–60).
Additional evidence also indicates that whereas GD3 enhances
apoptosis, 9-O-acetyl-GD3 has the opposite effect (61).
Recently, it has been reported that 5-N-deacetylation of GM3
(5-N-de-GM3), specifically expressed in metastatic melanomas,
but not in normal tissues or in the majority of primary melanomas
or benign nevi, correlates with an enhanced metastatic phenotype.
Furthermore, it has also been demonstrated that 5-N-de-GM3
stimulates cell migration and invasion by increasing the expres-
sion and activation of urokinase-like plasminogen activator and
matrix metalloproteinase-2. Thus, 5-N-de-GM3 can be considered
as a specific marker for metastatic melanoma and as a promising
immunotherapeutic target for cancer therapy (62).
Fucosyl-GM1 is a ganglioside with a unique structure in which
the terminal galactose is α-1,2-fucosylated at the non-reducing
end. It is expressed in very few normal tissues but occurs in a
variety of cancers such as in SCLC. Consequently, fucosyl-GM1
has also been considered to be a candidate as a tumor marker and
target antigen in antibody immunotherapy (63, 64).
TUMOR-ASSOCIATED GANGLIOSIDES: MOLECULAR
TARGETS FOR PASSIVE AND ACTIVE IMMUNOTHERAPIES
The use of antibodies to specifically target different cell popula-
tions has become a desirable method for treatment of a variety
of diseases, including cancer. In fact, cell surface receptors are the
main targets for immunotherapy due to the fact that they often play
important roles in tumor biology, where they are overexpressed or
display abnormal signaling. Basically, immunotherapeutic strate-
gies include the use of two types of immunization, passive and
active, with passive immunity being the transfer of humoral
immunity in the form of ready-made antibodies from one indi-
vidual to another (natural), or achieved by the artificial transfer
of antibodies that can be administered in several forms (human
or animal plasma or serum, such as pooled human immunoglob-
ulin or monoclonal antibodies). Passive immunotherapeutic can
also include the use of unlabeled antibodies, radiolabeled antibod-
ies, or antibody-drug conjugates, which is describe below. On the
other hand, active immunization is the induction of humoral or
cellular immunity after exposure to an antigen, which can occur
both naturally and artificially.
Glycolipids in general and gangliosides in particular, have
received considerable attention as a convenient immunotherapeu-
tic target for cancer treatment. This has resulted in the devel-
opment of a substantial number of potential passive and active
immunotherapies (Table 2; Figure 2B), of which some are briefly
described below.
IMMUNOTHERAPIES USING GANGLIOSIDE GM3 AS THE
TARGET
GM3 can be defined as a tumor-associated carbohydrate anti-
gen, since it is significantly overexpressed by a number of
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Table 2 | Immunotherapeutic strategies involving tumor associated gangliosides.
Ganglioside Type of tumor Type of treatment Type of
acquired
immunity
Reference
GM3 Melanoma mAb anti-GM3NPhAc 2H3 Passive Pan et al. (65)
Glycoengineered GM3NPhAc-KLH and ManNPhAc Active Qiu et al. (66), Wang et al. (67)
N -glycolyl GM3 ganglioside vaccine Active Carr et al. (68), Osorio et al. (69)
Anti-idiotype mAb (racotumomab) Active Vazquez et al. (57, 70)
Bladder cancer Addition of GM3 Passive Wang et al. (71)
GM2 Lymphoma mAb DMF10.167.4 (in vitro) – Fernandes et al. (72)
Melanoma and SCLC mAb DMF10.167.4 Passive Retter et al. (73)
Multiple myeloma
and SCLC
Hu-mAb BIW-8962 and KM8927 Passive Yamada et al. (74), Richardson et al. (75)
Melanoma GM2-KLH/QS-21 vaccine Active Slovin et al. (76), Eggermont et al. (77)
GD3 Melanoma mAb R24 Passive Nasi et al. (78)
Active Ravindranath and Morton (79)
Anti-GD3 chimeric sFv-CD28/T-cell Passive Lo et al. (36)
mAb anti-idiotype (BEC2) Active Grant et al. (80), McCaffery et al. (81)
R24 anti-anti-idiotype mAb Passive Ramos et al. (33)
mAb R24-saporin (in vitro) – Torres Demichelis et al. (32)
GD2 Melanoma Chimeric 14.18 Ab-IL-2 (in vitro) – Gillies et al. (82)
Hu-mAb L72 Passive Irie and Morton (83)
Immunotoxin 14.G2a mAb-ricin A (in vitro) – Wargalla and Reisfeld (84)
mAb anti-idiotype (1A7) Active Sen et al. (85, 86), Foon et al. (87, 88)
Immunocytokine chimeric 14.18 mAb-IL-2 Passive Becker et al. (89)
Neuroblastoma M-mAb 3F8/Hu-mAb 3F8 Passive Irie and Morton (83), Cheung et al. (90,
91), Kushner et al. (92)
M-mAb 14.G2a/M-mAb 14.G2a+ IL-2 Passive Mayer et al. (93), Frost et al. (94),
Handgretinger et al. (95)
Immunotoxins 14.G2a mAb-ricin A/BW704dgA Passive Gottstein et al. (96), Manzke et al. (97)
14.G2a chimeric T-cell receptors Passive Rossig et al. (98), Pulè et al. (99)
Anti-idiotype mAb (ganglidiomab) Active Lode et al. (100)
Immunocytokine chimeric 14.18 mAb-GM-CSF (in vitro) – Batova et al. (101)
Immunocytokine chimeric 14.18 mAb-IL-2 Passive Sabzevari et al. (102)
Fucosyl-GM1 SCLC mAb F12 and F15 Passive Brezicka et al. (103)
Fucosyl-GM1-KLH vaccine Active Dickler et al. (104)
9-O-Ac-GD2 SCLC, lymphoma,
neuroblastoma,
ovarian carcinoma
mAb 8B6 Passive Alvarez-Rueda et al. (105)
mAb, monoclonal antibody; M, mouse; Hu, human.
tumors, such as melanoma (39), and expressed at lower con-
centrations in many normal cells (106). It has been demon-
strated that unnatural N -acyl derivatives of GM3, especially
N -phenylacetyl GM3 (GM3NPhAc), were much more immuno-
genic than native GM3, and that GM3NPhAc could provoke a
robust T-cell dependent immune response in mice (65), which
is critical for the anti-tumor activities of a cancer immunother-
apy. More recently, some studies have demonstrated an effi-
cient metabolic glycoengineering of GM3 on melanoma cells
with monoclonal antibody-mediated selective killing of glyco-
engineered cancer cells. Basically, cells were metabolically labeled
both in vivo and in vitro with N -phenylacetyl-d-mannosamine
(ManNPhAc) and then a monoclonal antibody (2H3), which
recognizes both GM3NPhAc and ManNPhAc, was employed to
selectively target and kill metabolically glycoengineered cancer
cells (66, 67).
The immunogenic and toxicity profile of the heterophilic
Neu5Gc-GM3 ganglioside vaccine in patients with advanced
breast cancer was previously described. This vaccine, which is
formulated by the combination of gangliosides with the outer
membrane protein ofNeisseriameningitides to form very small size
proteoliposomes (VSSPs), resulted in acceptable safety outcomes.
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In addition, this technology permits an active immunotherapy
that involves activation of the potent innate natural immune sys-
tem (68). More recently, a Phase Ib/IIa clinical trial was carried
out in patients with advanced cutaneous and ocular malignant
melanomas in order to evaluate the immunogenicity and toxicity
of an intramuscularly administered cancer vaccine composed of
Neu5Gc-GM3/VSSP (69). The results obtained indicated the safety
and immunogenicity of the vaccine and reinforced the position of
gangliosides as targets for immunotherapy.
An attractive approach to generate an effective immune
response against tumor-associated antigens involves the use of
an anti-idiotype monoclonal antibody and appropriately selected
anti-idiotypic antibodies that can act as tumor-associated anti-
gen substitutes. As already mentioned above, although N -glycolyl
gangliosides are practically undetectable in normal human tis-
sues, these gangliosides are highly expressed in several human
cancer cells. For example, racotumomab is an anti-idiotype mon-
oclonal antibody specific to an antibody, which reacts to Neu5Gc-
containing gangliosides, sulfatides, and other antigens expressed in
tumors. This antibody was able to induce a strong anti-metastatic
effect in tumor-bearing mice (70), and more recently, a Phase II/III
multicenter double-blind clinical trial was conducted to evalu-
ate the effects of racotumomab vaccine in the overall survival
in patients with advanced non-SCLC. The results of this study
showed a significant clinical benefit in the patients who were
treated with the anti-idiotype vaccine (57).
IMMUNOTHERAPIES USING GANGLIOSIDE GM2 AS THE
TARGET
Ganglioside GM2 is involved in cell adhesion and signal trans-
duction, and it has also been reported to play a role in tumor
metastasis. As normal cells express little GM2, it is an ideal tar-
get for anti-metastatic therapy. Related to this, DMF10.167.4 is a
hamster monoclonal antibody raised against a murine T-cell lym-
phoma cell line and has been shown to induce apoptosis in vitro
(72). This antibody was found to react with a GM2 epitope that
is expressed on a large number of tumor cell lines, including
human melanoma and SCLC, but not on normal primary lines
or most normal tissues (73). It was shown to have immunother-
apeutic potential, since it was able both to prevent tumors being
established in vivo and to block the progression of established
tumors.
The anti-metastatic effects of the two humanized anti-
ganglioside GM2 antibodies, BIW-8962 and KM8927, have been
recently investigated and compared with the chimeric anti-GM2
antibody KM966, in a mouse model of multiple organ metastases
induced by GM2-expressing SCLC cells (74). These humanized
antibodies inhibited the production of multiple organ metas-
tases, increased the number of apoptotic cells, and prolonged the
survival of the mice, which suggests that humanized anti-GM2
antibodies may be therapeutically useful for controlling multiple
organ metastases of GM2-expressing SCLC.
GM2 ganglioside has also been used for vaccination in combi-
nation with a T-cell carrier such as keyhole limpet hemocyanin
(KLH), or with other adjuvants such as purified mycobacter-
ial cell-wall skeleton or QS-21, a saponin-based adjuvant. The
GM2-KLH vaccine not only induced a IgM response, but also
induced durable IgG antibodies in most patients in early clinical
trials (76). Nevertheless, a recent study shows that GM2-KLH/QS-
21 vaccination does not improve the outcome for patients with
stage II melanoma (77).
IMMUNOTHERAPIES USING GANGLIOSIDE GD3 AS THE
TARGET
The ganglioside GD3 is a glycolipid highly expressed during the
early developmental stages of the central nervous system, when
the neural cells proliferate actively. At later developmental stages,
the GD3 content declines and other gangliosides become more
abundant (107, 108) with the expression level of GD3 being
very low and restricted in adult extra neural tissues. However,
GD3 is highly expressed in tumor cells in more than 80% of
melanomas. It is also overexpressed in neuroectodermal tumors
(neuroblastoma and glioma) and carcinomas (36). For these rea-
sons, ganglioside GD3 has received considerable attention as a
promising immunotherapeutic target for cancer therapy. As such,
it has been used for passive (78) and active (79) immunother-
apy of melanoma cancer. However, the results obtained with
this antibody therapy are modest (76), and the generation of
new GD3-specific chimeric antigen receptors with improved
efficacy in human primary T-lymphocytes is currently being
evaluated (36).
Many studies have also involved the use of anti-idiotype vaccine
in cancer patients, which mimics GD3 ganglioside (109). In partic-
ular, the monoclonal antibody Bec2 has been studied in melanoma
and SCLC patients, where it induced specific anti-GD3 antibod-
ies, but only in a low percentage of patients (80, 81). Later, a
Phase III clinical trial with 515 SCLC patients revealed a major
response to chemotherapy and chest radiation with this antibody.
Although this trial failed to show any survival advantage for vac-
cinated patients, a trend toward prolonged survival was observed
in those patients who developed the humoral response (110).
The mouse monoclonal R24 antibody (IgG3), directed against
ganglioside GD3, is a validated tumor targeting agent that has
shown strong cell surface reactivity for a range of human
melanoma cell lines and other epithelial tumor cancer cells (40).
It was demonstrated in our laboratory that, for different cell lines,
the R24 antibody to GD3 was rapidly endocytosed after binding
to the disialoganglioside at the cell surface before being sorted
to early endosomes and later accumulated in REs (111). There-
fore, its rapid internalization in cells precludes its use as a “naked
therapeutic antibody,” because when internalized it cannot link to
pathways of complement- or cellular-dependent anticancer activ-
ities. However, we took advantage of the internalization feature
of R24 antibody for selective delivery of the toxin saporin (a
ribosome-inactivating protein) to GD3-expressing cells (32). This
was carried out using a goat anti-mouse IgG antibody linked to the
ribosome-inactivating toxin, and additionally, biotinylated R24
antibody was used for targeted delivery of streptavidin-saporin.
This immunotoxin was found to be specifically cytotoxic for GD3-
expressing cells [human (SK-Mel-28) and mouse (B16) melanoma
cells and Chinese hamster ovary-K1 cells] grown on 2D mono-
layers and for cells grown in attachment-free conditions. Thus,
ganglioside GD3 emerge as a novel and attractive class of cell sur-
face molecule for the targeted delivery of cytotoxic agents, and
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therefore, provides a rationale for future therapeutic intervention
in cancer.
IMMUNOTHERAPIES USING GANGLIOSIDE GD2 AS THE
TARGET
GD2 is a disialoganglioside normally expressed on skin
melanocytes, neurons, and peripheral nerves. It is overexpressed
in cancers such as neuroblastoma, melanoma, glioma, some types
of non-SCLC (112) and also in sarcomas (64), and thus is a
promising target to treat these types of cancers. In fact, target-
ing GD2 has the important advantage that is not shed by cells
into the microenvironment (113), in contrast with other studied
gangliosides (114). Many antibodies that target this ganglioside
have been studied, with Hu-mAb L72 being shown to react specif-
ically with ganglioside GD2 and have a strong cytotoxic effect
on human melanoma cells in the presence of complement (83).
The 3F8 antibody has been assessed in clinical trials in patients
with neuroblastoma (90, 92). Humanizing m3F8 produced anti-
GD2 antibodies with an increased ADCC potential in vitro and
anti-tumor activity in vivo, also reduced pain and human anti-
mouse antibody side effects (91). However, in a recent report,
posterior reversible encephalopathy syndrome (PRES) in neurob-
lastoma patients receiving anti-GD2 3F8 was documented (115).
The use of 14.G2a mouse monoclonal antibody showed granu-
locyte mediated ADCC in neuroblastoma cells in vitro (93), and
when administrated to patients concomitantly with IL-2 (94).
When the effect of an immunotoxin covalently linking ricin
A chain toxin to 14.G2a mouse monoclonal antibody was eval-
uated, cytotoxic activity of this immunocomplex against human
tumor cells was reported in vitro (84) and in a disseminated human
neuroblastoma in a severe combined immunodeficiency (SCID)
mice model (96). In addition, it was described the antitumoral
capacity of two immunotherapeutic approaches using GD2 bind-
ing BW704 antibody conjugated to deglycosylated ricin A and
to an anti-CD3× anti-GD2 bispecific antibody that was capable
of redirecting cytotoxic T-cells toward neuroblastoma cells. The
results obtained in vitro and in vivo suggest a potential role of these
immunotherapeutic agents in the treatment of minimal residual
disease in the advanced stages of neuroblastoma (97).
Anti-idiotype antibodies have also been investigated with
respect to their ability to overcome difficulties and activate an
appropriate immune response when GD2 ganglioside is used as
immunogen. In one study, ganglidiomab was generated follow-
ing immunization of Balb/c mice with 14G2a and splenocytes
were then harvested to generate hybridoma cells. It was demon-
strated induction of a GD2-specific humoral immune response
after vaccination of mice with ganglidiomab effective in mediating
GD2-specific killing of neuroblastoma cells (100). In other inves-
tigations, the murine monoclonal anti-ganglioside GD2 antibody
14.G2a was used to generate the monoclonal anti-idiotype 1A7
(85) which has been used as an anti-idiotype vaccine in patients
with advanced melanoma (87, 88). Immunization with this anti-
idiotype vaccine elicited a strong anti-GD2 antibody response
that specifically reacted with tumor cells expressing GD2 with the
results suggesting that this anti-idiotype vaccine may have a role
in preventing disease progression and in increasing the survival
time for patients with advanced malignant melanoma (87).
Antibody-cytokine fusion proteins, designed to achieve optimal
biological effectiveness by combining the unique targeting ability
of antibodies with the multifunctional activities of cytokines (82,
116), have been also used as cancer vaccine. In addition, immuno-
cytokines have been generated by fusion of a human/mouse
chimeric anti-ganglioside GD2 antibody (ch14.18) with cytokines
GM-CSF and IL-2, and proved to be effective in killing GD2 pos-
itive cells in vitro by CDC and ADCC mediated by granulocytes
(101). The ch14.18-IL-2 fusion protein was also shown to have
provided anti-tumor effects in SCID mice bearing human tumor
xenografts of neuroblastoma (102) and melanoma (89).
9-O-Ac-GD2 ganglioside is a modified GD2 ganglioside which
is expressed in neuroblastoma, SCLC, melanoma, and renal car-
cinoma, but not in peripheral nerve fibers, ovarian carcinoma, or
pancreatic carcinoma (105). A monoclonal antibody to O-acetyl-
GD2, 8B6, was developed and showed (both in vitro and in vivo)
anti-tumor properties that were comparable to those elicited by
anti-GD2 14.G2a. More recently, it was further demonstrated that
the 8B6 antibody was very effective in suppression of tumor growth
in mice by reducing the cell proliferation index and inducing apop-
tosis. Moreover, it was also observed that the lytic function of
NK cells and complement were not a requirement for the in vivo
activity of the 8B6 antibody (117).
IMMUNOTHERAPIES USING GANGLIOSIDE FUCOSYL-GM1
AS THE TARGET
Fucosyl-GM1 is a characteristic glycolipid expressed in SCLC cells,
which is detected with high frequency in SCLC in comparison
with other cancers of the lung or in normal lungs or bronchus
(with it only being sporadically expressed, if at all, in normal tis-
sues) (45, 64). However, the immune system does not seems to be
able to respond against this fucosylated glycolipid, as there is no
production of auto-antibodies (118). The fact that it is an exclu-
sively antigen expressed on SCLC cells turns it into an appropriate
candidate for therapy. Related to this, two monoclonal antibod-
ies against fucosyl-GM1 (F12 and 15) induced CDC and ADCC
in fucosyl-GM1 expressing cell lines in vitro, and also conferred
protection against tumor engraftment in a mouse model (103). In
clinical trials of immunization with fucosyl-GM1-KLH conjugate,
SCLC patients demonstrated serological IgM and IgG responses
against fucosyl-GM1 and in vitro CDC of fucosyl-GM1 positive
cell lines (104). When the conjugate was produced using synthetic
fucosyl-GM1 (119), the IgM response and in vitro CDC were com-
parable to those obtained with the natural fucosyl-GM1 conjugate
but without the IgG response. Finally, in a recent study, it was also
suggested as a potential marker of hepatocellular carcinoma (120).
CONCLUDING REMARKS
Over recent decades, a substantial number of cancer immunother-
apies have been developed, that have used the sialosylated glycol-
ipids as the main target (see Table 2; Figure 2B). Although many of
these therapies have failed to result in a significant effect on tumor
development, others have led to promising results. We have learnt
about how we can address an immune response to a specific cell
surface ganglioside, but certainly, there is still much to do in terms
of improving these immunotherapies. With the advent of mod-
ern technologies, new and combinatorial immunotherapies are
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currently being developed in an attempt to overcome some of the
limitations of using glycolipids as vaccine antigen, such as their
poor immunogenicity, low-affinity immunoglobulin responses,
and immunotolerance. In this sense, mimetic peptides represent
a very promising tool to overcome T-cell independence of some
carbohydrate antigens. The development of DNA vaccine encod-
ing designed peptide mimotope (minigene) of GD2 ganglioside
has been demonstrated to be effective in inducing protective GD2
cross-reactive IgG antibody responses (121, 122). As also pro-
posed, engineering the mimotope into a hybrid plasmid, which
can also include cytotoxic T-lymphocyte epitopes from a tumor
target itself, would be expected to build an effector response that
could improve the tumor-protective immunity evoked by the
minigene vaccine (121). Finally, studies are also being focused
on the development of new strategies for therapeutic intervention
in cancer, which propose the use gangliosides for targeted delivery
of cytotoxic agents via specific antibodies (32), or eventually, via
small-molecule cyclic peptide ligands (123).
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